ReviewReviews of physiology, biochemistry and pharmacology2020
CXC Chemokine Receptors in the Tumor Microenvironment and an Update of Antagonist Development.
Review in Reviews of physiology, biochemistry and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- C-X-C chemokine receptor family genes in osteosarcoma: expression profiles, regulatory networks, and functional impact on tumor progression.Hereditas · 2025Article
- CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.Medical oncology (Northwood, London, England) · 2025Review
- Review
- CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent.Frontiers in pharmacology · 2025Review
- Low CXCR6 expression drives extracellular matrix remodeling and enhances cell proliferation in OSCC.Genes & diseases · 2025Article
- Analyzing the Functional Roles and Immunological Features of Chemokines in COAD.International journal of molecular sciences · 2024Article
- Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer.Frontiers in genetics · 2024Article
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Small molecule-based immunomodulators for cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction.Annals of translational medicine · 2022Article
- Rethinking the chemokine cascade in brain metastasis: Preventive and therapeutic implications.Seminars in cancer biology · 2022Review
- Expression profile and prognostic value of CXCR family members in head and neck squamous cell carcinoma.World journal of surgical oncology · 2022Article
- The Network of miRNA-mRNA Interactions in Circulating T Cells of Patients Following Major Trauma - A Pilot Study.Journal of inflammation research · 2022Article
- Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.Frontiers in oncology · 2021Article
- Identification and Comprehensive Prognostic Analysis of a Novel Chemokine-Related lncRNA Signature and Immune Landscape in Gastric Cancer.Frontiers in cell and developmental biology · 2021Article
- Characterization of the Prognostic Values of the CXCR1-7 in Clear Cell Renal Cell Carcinoma (ccRCC) Microenvironment.Frontiers in molecular biosciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine receptors, a diverse group within the seven-transmembrane G protein-coupled receptor superfamily, are frequently overexpressed in malignant tumors. Ligand binding activates multiple downstream signal transduction cascades that drive tumor growth and metastasis, resulting in poor clinical outcome. These receptors are thus considered promising targets for anti-tumor therapy. This article reviews recent studies on the expression and function of CXC chemokine receptors in various tumor microenvironments and recent developments in cancer therapy using CXC chemokine receptor antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.